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1. Introduction 
This chapter will describe various treatment options for infective conjunctivitis, allergic 
conjunctivitis, conjunctivitis in immunological disorders and other varieties of conjunctivitis 
that can be effectively managed in general practice whilst also highlighting various RCTs 
and systematic reviews on treatment of conjunctivitis. 
The conjunctiva is a vascularised mucus membrane that covers some anterior portion of the 
globe and the inner aspects of eye lids. Like all mucous membranes, it also consists of 
epithelial and stromal layers. The continuum of the epithelial cell layer occurs in one side 
with epidermis of the lids at the lid margin and with the corneal epithelium at the limbus. 
Because of this anatomical architecture we call this pouch as conjuctival cul-de sac. The 
conjunctiva has enormous potential for combating infections mainly because of a) high 
vascularity b) different types of cells present in conjunctiva initiating and participating in 
defence inflammatory reactions c) immunopotent cells present in conjunctiva d) enzymatic 
activity of conjunctiva neutralising many pathogens including viruses. However the 
conjunctival sac is rarely sterile and is prone to external insult as well as victim of 
immunological reactions. It has been found that the normal conjunctival flora shares 
organisms with the skin and respiratory tract. The major organisms found are 
Staphylococcus, Diptheroids, Anaerobes, Streptococcus, Pneumococcus, Hemophilus, E.Coli etc. 
However, as most of these potential pathogens are in their dormant stage, they rarely cause 
infection. Bacterial or infective conjunctivitis is mainly due to organisms of exogenous 
source. Though many forms of such infections are self-limiting because of barrier function of 
the conjunctival epithelium, there are exceptions for certain virulent organisms such as 
N.gonorrhea, Listeria monocytogens ,Corynobacterium diptheriae and the Haemophilus group. 
These bacteria possess proteolyitic enzymes which damage the parenchymal structure of the 
conjunctiva. Some conjunctival infections may signify an underlying disease something 
more sinister such as a systemic disease. In neonates, infective conjunctivitis poses a greater 
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threat to the vision in comparison to adult varieties and therefore any visual problems must 
be assessed thoroughly. 
1.1 Role of general practitioner in managing conjunctivitis 
The majority of conjunctivitis cases report to their general practitioner for initial 
management. In a study in 1992, most general practitioners expressed confidence of 
managing conjunctivitis by themselves although many expressed that to refer the cases later 
if necessary. (Featherstone P I et al 1992)  
The general practitioner needs to be well versed in diagnosing the type of conjunctivitis and 
rendering initial advices to the sufferer. Although conjunctivitis looks like a minor ailment, 
it can be frustrating and has social implications especially at work places. 
1.2 Guidelines for GPs in achieving the following goals 
 Identify patients at risk of developing conjunctivitis 
 Accurately diagnose conjunctivitis of diverse origins 
 Improve the quality of care rendered to patients with conjunctivitis 
 Initiate appropriate treatment for conjunctivitis 
 Reduce the potentially adverse effects of conjunctivitis 
 Inform and educate patients and other health care providers about the diagnosis and 
management of conjunctivitis. 
2. Management of conjunctivitis 
It is essential to differentiate conjunctivitis from other vision threatening conditions that 
produce red eye such as in acute congestive glaucoma and uveitis. The GP should try to 
extract as much information from history taking. The second task with them is to find out 
the type of conjunctivitis. Cases with bacterial conjunctivitis will most likely present with 
white discharge, whilst watering of the eye has been associated with viral conjunctivitis. 
Itching is a prominent symptom in case of allergic conjunctivitis. Other forms of 
conjunctivitis such as in immunological disorders can be identified after finding some form 
of clinical clue during systemic examination. While managing cases of conjunctivitis, general 
practitioners must try to avoid contaminating themselves as well as clinic items. 
2.1 Management of bacterial conjunctivitis 
Although most cases of bacterial conjunctivitis run through benign course and self-healing, 
depending on the immune status of the patient, it might lead to severe lasting and with 
threat to vision too. As mentioned earlier, bacterial conjunctivitis usually presents with 
sticky eyes with white discharges. Unilateral conjunctivitis may be due to chemical, toxic, 
mechanical factors or may be due to the involvement of lacricamal gland or even a case of 
glaucoma, which the GP should be aware of while treating them. 
Although there has been a tremendous decrease in incidence of most dangerous varieties of 
bacterial conjunctivitis such as caused by Gonococcus and Diphtheria, bacterial conjunctivitis 
still continues as commonest type of conjunctivitis in developing nations. The outbreak is 
usually during monsoon season. Conjunctival discharge (usually white) used to be the main 
diagnostic feature apart from red and gritty eye as major complains. Once a GP is certain of 
bacterial conjunctivitis, their first approach would be to clean the discharge with cotton 
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soaked with warm water, and to explain the same procedure to the patients, so they can do 
in home before applying medications. Generally most of the bacterial conjunctivitis cases are 
treated as outpatient cases but whenever any corneal involvement is suspected it would be 
ideal to treat the patient as an inpatient. 
 
 
Fig. 1. Bacterial conjunctivitis (Look for the mucous discharge) 
There are three categories of approaches of treating conjunctivitis in a GP setting; no use of 
antibiotic eye drops, delayed use of antibiotics and early use of antibiotics in conjunctivitis. 
(Everitt HA 2006). 
The fundamental treatment of bacterial conjunctivitis is application of topical antibiotics. 
However, the pattern of antibiotics prescription varies in different practices. Most GPs 
prefer to start with broad spectrum antibiotics. The most commonly used broad-spectrum 
antibiotics are Ciloxan (ciprofloxacin) or Ocuflox (ofloxacin), Gatifloxacin ,which are 
commonly prescribed. Sulfacetamide is also acceptable though not commonly used now 
days. Although aminoglycosides like Gentamycin and Tobramycin are often used they 
sometimes retard epithelial healing process, and so they should be used with caution. 
Polytrim (trimethoprim/sulfamethoxazole) is a reasonable choice particularly in children. 
Chloramphenicol eye drop is also a preferred choice especially in developing countries 
where the common organisms responsible are gram positive bacteria. The usual practice is 
to instil drops every 2 hours, although there is also an ointment that can be used at night or 
every 4-6 hours throughout the day. 
To give a better idea on effectiveness of various topical antibiotics used in bacterial 
conjunctivitis we are quoting few study reports below. 
A) Study on fluoroquinolone group of topical antibiotics: 
One randomized, multicenter, double-masked, vehicle-controlled study, with a total of 957 
patients aged 1 year and older with bacterial conjunctivitis were randomized to treatment 
with besifloxacin ophthalmic suspension 0.6% or vehicle applied topically three times daily 
for 5 days. It has been found that: 
Three hundred and ninety patients had culture-confirmed bacterial conjunctivitis. Clinical 
resolution and microbial eradication were significantly greater with besifloxacin ophthalmic 
suspension than with vehicle at Visit 2 (45.2% vs. 33.0%, p = 0.0084; and 91.5% vs. 
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59.7%, p < 0.0001, respectively) and Visit 3 (84.4% vs. 69.1%, p = 0.0011; and 88.4% vs. 
71.7%, p < 0.0001, respectively). They had expressed that the results of secondary endpoints 
of individual clinical outcomes were consistent with primary endpoints. They also found 
that only few eyes receiving besifloxacin ophthalmic suspension experienced adverse events 
than those receiving vehicle (9.2% vs. 13.9%; p = 0.0047). They concluded by saying that the 
Besifloxacin ophthalmic suspension produced clinical resolution and microbial eradication 
rates significantly better than vehicle and was safe for the treatment of bacterial 
conjunctivitis. (Michael E T 2009) 
In one recent comparative study on currently prescribed antibiotics in bacterial 
conjunctivitis, the authors evaluated the speed of clinical efficacy for two currently available 
topical antibiotics: polymyxin B sulfate/trimethoprim (polymyxin/trimethoprim) and 0.5% 
moxifloxacin ophthalmic solution. They had enrolled eighty-four eyes of 56 patients 
younger than 18 years with a clinical diagnosis of bacterial conjunctivitis in a multicenter 
study. Patients were randomly assigned to receive either 1 drop of polymyxin/ 
trimethoprim four times daily for 7 days or 1 drop of 0.5% moxifloxacin three times daily for 
7 days. Ocular signs and symptoms were evaluated at baseline and 24 and 48 hours after the 
start of dosing. Microbiological cultures were collected at baseline and 48 hours. They had 
noted patients rated ocular symptoms and adverse events on day 7 via telephone interview. 
They had included primary efficacy assessment as relief of all signs and symptoms of 
bacterial conjunctivitis. According to their reports all patients bar one completed all visits. 
At the 48-hour visit, complete resolution of ocular signs and symptoms was observed in 81% 
of the patients treated with moxifloxacin and 44% of the patients treated with 
polymyxin/trimethoprim (P = .001). No adverse events were reported in both the groups. 
They concluded by saying that Moxifloxacin 0.5% administered three times daily was safe 
and could cure bacterial conjunctivitis more effectively and significantly faster than 
polymyxin/trimethoprim dosed four times daily. The majority of patients were cured and 
symptom-free by 48 hours. They commented that moxifloxacin is cost-effective and 
significantly more efficacious than polymyxin/trimethoprim in the speed by which it 
reduced the symptoms and disease transmission. (Granet DB 2008) 
B) Study on  aminoglycoside group of topical antibiotics: 
Similarly, one more comparative study was done for Gentamycin and Merimycin topical 
preparations in bacterial conjunctivitis. That study compared the clinical and microbiologic 
value of topical netilmicin with that of gentamicin in the treatment of acute bacterial 
conjunctivitis. It was a double-blind, randomized, prospective, controlled study, which was 
performed in 209 patients. One to two drop(s) of either antibiotic was applied to the affected 
eye(s) four times a day for up to 10 days. They examined the cases at the time of diagnosis 
and after 3, 5, and 10 days. Clinical efficacy was measured as the cumulative sum score 
(CSS) of the key signs and symptoms of acute bacterial ocular infection. 
Sensitivity/resistance was evaluated using the disk diffusion method. The drug efficacy 
assessment was restricted only to patients with positive baseline culture results (n = 121) in 
that study. Of the isolated organisms, 96.9% were sensitive to netilmicin, whereas only 
75.0% were sensitive to gentamicin (p = 0.00001). They also observed that Netilmicin 
provided a broad-spectrum coverage comparable with that of ciprofloxacin, ofloxacin, and 
norfloxacin. Netilmicin also was more effective than gentamicin in eradicating infections 
(p = 0.001 at day 5 and p = 0.037 at day 10) and in ameliorating the CSS (p = 0.037 at day 
3, p = 0.001 at both day 5 and day 10). Only minor adverse events occurred in patients 
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treated with either netilmicin or gentamicin. They concluded by saying that netilmicin was a 
safe and effective antibiotic that could be used as first-line therapy for the treatment of acute 
bacterial conjunctivitis. (Papa V 2002) 
A study in Canada done by Jackson WB compared 1% fucidic acid viscous drop with 0.3% 
tobramycin eye drop in treating acute bacterial conjunctivitis and came with the conclusion 
that the clinical and bacteriologic efficacy of fusidic acid viscous drops combined with the 
convenience of a twice-daily dosage regimen establishes this antibiotic as first-line treatment 
for suspected acute bacterial conjunctivitis and a favourable alternative to other broad-
spectrum antibiotics. 
C) Recent study reports on Azithromycin eye drop: 
Of late, studies on the use of Azithromycin in bacterial conjunctivitis provide some 
positive responses. Azithromycin 1% showed successful therapeutic intervention because 
therapy could be completed with 7 drops administered over 5 days, whilst high 
bactericidal levels were sustained in the eye overnight. they believed that there was the 
potential for reduction in the development of resistance by effectively killing sensitive 
organisms. (Friedlaender MH 2007).  
Similarly, another study in 2008 showed that the topical therapy with azithromycin 1.5% 
administered only twice daily for 3 days effectively eradicated most pathogenic bacteria 
associated with bacterial conjunctivitis. Those microbiologic results were in accordance with 
the observed clinical outcome. The study claimed that the new anti-infective product had 
the advantage of a short treatment course which could lead to an improvement in patient 
compliance. (Denis F 2008) 
One more study highlighted the kinetics of Azithromycin in treating bacterial conjunctivitis. 
This study tested the hypothesis that azithromycin demonstrates a bactericidal, 
concentration-dependent antibiotic effect at concentrations corresponding to and exceeding 
published tear and conjunctival levels. The antibacterial activity of different concentrations 
of azithromycin 1% in DuraSite® (AzaSite®; Inspire Pharmaceuticals Inc, Durham, NC, 
USA) was evaluated in this study by using a kinetics-of-kill model. Recent conjunctivitis 
isolates of Staphylococcus aureus, Streptococcus pneumoniae or Haemophilus influenzae were 
exposed to four concentrations of azithromycin (100, 250, 500 and 750 μg/ml). Starting 
concentrations were similar to the maximum concentrations (Cmax) that have been 
demonstrated in conjunctiva (83 μg/g) and tears (288 μg/ml) following topical ocular 
administration. The percentage of surviving bacteria at 30 and 60 minutes following 
exposure to each concentration were determined. Azithromycin failed to demonstrate 
bactericidal activity (i.e. a 3-log reduction in surviving bacteria) against S. aureus, S. 
pneumoniae or H. influenzae. Furthermore, the rate and extent of antibacterial activity with 
azithromycin did not change with higher concentrations, even at the highest tested 
concentration of 750 μg/ml .They concluded by saying that azithromycin demonstrated 
bacteriostatic activity against common conjunctival pathogens up to the maximum tested 
concentration of 750 μg/ml (i.e. 2.6-times and 9-times published Cmax tear and conjunctival 
concentration, respectively). Azithromycin’s bacteriostatic effects and prolonged elimination 
half-life would likely lead to a corresponding increase in the emergence of macrolide-
resistant isolates. (Mark S 2008) 
The advantages of Azithromycin eye drop in bacterial conjunctivitis is its shorter duration of 
effective treatment. In one comparative study the authors compared the three day treatment 
bacterial conjunuctivitis with 1.5% Azithromycin eye drop versus 7 days treatment with 
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Tobramycin eye drop. They compared the efficacy and safety of Azyter, azithromycin 1.5% 
eye drops, for 3 days with tobramycin 0.3% for 7 days to treat purulent bacterial 
conjunctivitis. That was a multicentre, randomised, investigator-masked study including 
1043 children and adults with purulent bacterial conjunctivitis. Patients received either 
azithromycin 1.5% twice-daily for 3 days or tobramycin 0.3%, 1 drop every two hours for 2 
days, then four times daily for 5 days. Clinical signs were evaluated and cultures obtained at 
D0, D3 and D9 (where D refers to “day”). Primary variable was the clinical cure at the Test-
of-Cure (TOC)-visit (D9±1), for patients with D0-positive cultures. The cure was defined as: 
bulbar conjunctival injection and discharge scores of 0.They documented that among 471 
patients with D0-positivity in the per protocol set, 87.8% of the azithromycin 1.5% group 
and 89.4% of the tobramycin group were clinically cured at the TOC-visit. Azithromycin 
was non-inferior to tobramycin for clinical and bacteriological cure. Clinical cure was 
significantly higher with azithromycin 1.5% at D3. The safety profile of azithromycin was 
satisfactory with a good patient and investigator’s acceptability. They concluded by saying 
that Azithromycin 1.5% for 3 days was as effective and as safe as tobramycin for 7 days. 
Furthermore, more azithromycin than tobramycin patients presented an early clinical cure 
at Day 3. Due to its twice daily dosing regimen for 3 days, azithromycin represents a step 
forward in the management of purulent bacterial conjunctivitis, especially in children. 
(Isabelle C 2006) 
To start or not start antibiotics, or a delayed start of antibiotics? 
There has been debate on this question. We quote few study reports which did not find much 
difference in antibiotic treated group and those not given antibiotics. 
In one of the Cochrane systematic reviews the meta analysis reveals that acute bacterial 
conjunctivitis is frequently a self-limiting condition, as clinical remission occurred by days 2 to 
5 in 64% (95% confidence interval (CI) = 57-71) of those treated with placebo. But the treatment 
with antibiotics was, however, associated with significantly better rates of clinical remission 
(days 2 to 5: relative risk (RR) = 1.31, 95% CI = 1.11-1.55), with a suggestion that this benefit 
was maintained for late clinical remission (days 6 to 10: RR = 1.27, 95% CI = 1.00-1.61).They 
concluded by saying that the acute bacterial conjunctivitis is frequently a self-limiting 
condition but the use of antibiotics is associated with significantly improved rates of early 
clinical remission, and early and late microbiological remission. (A Sheikh and B Hurwitz). 
Similarly, one randomised control trial involving 30 GP centres in UK, Everitt HA et al 
compared the three management strategies; no antibiotic, immediate antibiotic and delayed 
antibiotic and came to a conclusion that the delayed prescribing approach may be the best 
approach. Compared with no initial offer of antibiotics, delayed prescribing had the 
advantage of reduced antibiotic use (almost 50%), no evidence of hospitalisation, similar 
symptom control to immediate prescribing, and reduced re-attendance for eye 
infections.(Everitt HA 2006) 
In view of antibiotic eye drops being costly in various parts of developing countries an 
alternate way of treating with povidone iodine, especially in children, can serve as 
alternative. This was documented in one of the studies, which was done to report the 
efficacy of povidone-iodine as a treatment for conjunctivitis in paediatric patients. It was a 
double-masked, controlled, prospective clinical trial. The study was done in a general 
hospital in Manila, Philippines, 459 children (mean (SD) age 6.6 (6.6) years; range, 7 months-
21 years) with acute conjunctivitis were studied. Infected eyes were cultured for bacteria 
and underwent immunofluorescent testing for Chlamydia trachomatis. Viral conjunctivitis 
was diagnosed if bacterial cultures were negative and diagnostic criteria were met. Subjects 
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were alternated to receive povidone-iodine 1.25% or neomycin-polymyxin-B-gramicidin 
ophthalmic solution, one drop 4 times daily in the affected eye. Ocular inflammation was 
evaluated daily by the family or patient and weekly by an ophthalmologist. The main 
outcome measures were days until cured and proportion cured after 1 and 2 weeks of 
treatment. It was found that despite adequate statistical power (power >80% for a 1-day 
difference and P < .05), there was no significant difference between treatment groups 
regarding the number of days to cure or proportion cured at 1 or 2 weeks whether caused 
by bacteria or virus (P = .133–.824 for the four comparisons). After 1 week of treatment, 
povidone-iodine cured marginally more chlamydial infections than the antibiotic (P = 
.057). By 2 weeks, fewer chlamydial infections were cured than those of viral or bacterial 
etiology (P = .0001). The younger the patient, the faster their conjunctivitis resolved (R = 
0.13, P = .013).The authors concluded in saying that  povidone-iodine 1.25% ophthalmic 
solution was as effective as neomycin-polymyxin B-gramicidin for treating bacterial 
conjunctivitis, somewhat more effective against chlamydia, and as ineffective against viral 
conjunctivitis. Povidone-iodine ophthalmic solution should be strongly considered as 
treatment for bacterial and chlamydial conjunctivitis, especially in developing countries 
where topical antibiotics are often unavailable or costly. (Sherwin JI 2002) 
The overall idea of a successful treatment of bacterial conjunctivitis is to go for proper 
diagnosis and follow up. GPs should restrain themselves from early initiation of antibiotics; 
rather follow the case with maintenance of ocular hygiene. The choice of antibiotic should 
also measure cost effectiveness and availability. And worsening of symptoms and signs 
should prompt GPs in referring cases to the Consultants. 
It is interesting to note that in one of the studies comparing treatment with different 
antibiotics, it did not demonstrate that any one antibiotic is superior. It said that the choice 
of antibiotic should be based on consideration of cost and bacterial resistance. The present 
practice of prescribing antibiotics in most cases is not necessary. (Rose P 2007) 
Although the very severe form of conjunctivitis resulting from gonococcal infections are 
always referred and treated by consultants, GPs should have knowledge on treatment and 
preventative measures of gonoccocal conjunctivitis. Infection by N gonorrhoeae in the newborn 
also requires systemic treatment of the neonate, the mother, and at-risk contacts. In usual 
practice, general practitioners refer the cases for consultant’s intervention. The neonate may be 
treated with intravenous aqueous penicillin G 100 units per kg per day in 4 divided doses for 1 
week. The mother and at-risk contacts may be treated with a single dose of intramuscular 
ceftriaxone 125 mg followed by oral doxycycline 100 mg twice daily for 7 days. Common 
regime for prophylaxis for such occurrence is by instillation of 1% silver nitrate solution, 1% 
tetracycline ointment, or 0.5% erythromycin ointment just after birth. Patients with gonococal 
conjunctivitis should be seen daily until resolution of conjunctivitis at the same time each case 
should be simultaneously treated for Chlamydia trachomatis infection. 
2.2 Management of viral conjunctivitis 
Viral induced conjunctivitis is another form of conjunctivitis and although self limiting in 
many cases, they take longer duration for healing. The most common viral organisms 
responsible for this form of conjunctivitis are Herpes simplex virus (HSV), Varicella Zoster 
virus (VZV), pox virus, measles virus, immunodeficiency virus (HIV) etc. In all these forms 
of conjunctivitis, the common presentation is the development of conjunctival follicles, 
which arise due to hypertrophied lymphoid tissue caused by the inflammatory reaction 
from the viral presence. 
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Fig. 2. Viral conjunctivitis (Look for pink eye without any discharge) 
Herpes infection of the eye may be acquired as the patient's first exposure to the virus 
(primary infection) or as involvement of a new anatomical site (the eye) in a patient with 
previous HSV infection. In either case, patients with herpetic eye infection risk recurrent eye 
disease throughout their lives. The infective lesions of the corneal epithelium (dendritic and 
geographic ulcers) occasionally develop into non-infective indolent or trophic ulcers, 
particularly under the influence of cauterizing chemicals or corticosteroids. Inflammation of 
the corneal stroma may accompany herpetic epithelial lesions or occur independently. 
Stromal keratitis probably represents the host's immune response to viral antigens filtering 
down from epithelial lesions or from viral replication in stromal cells. 
The choice of the optimal technique for diagnosing viral and chlamydial keratoconjunctivitis 
depends upon the efficiency, speed, and cost of the test. The performance of conventional 
laboratory procedures is relatively poor, and the interpretative difficulties documented with 
these tests are well recognised. Owing to their inherent sensitivity and high specificity, 
nucleic acid amplification procedures, in particular PCR, are recognised as the ultimate 
modern diagnostic tool for the identification of adenovirus, HSV, and C trachomatis in 
clinical eye swab samples. However, in laboratories without access to PCR, the conventional 
techniques of enzyme immunoassay, culture. (Elfath ME et al 1999) 
Most cases of viral conjunctivitis, like that caused by adenovirus, need supportive 
treatment. No evidence exists that demonstrates efficacy of antiviral agents. Patients 
should be instructed to use cold compresses and lubricants, such as artificial tears, for 
comfort and symptom relief. For some susceptible individuals, a topical astringent or 
antibiotic may be used to prevent a bacterial super infection. Extreme caution should be 
taken when using corticosteroids, as they may worsen an underlying HSV infection. 
Recent reports suggest there is a beneficial effect of topical iodine povidone-iodine at a 
concentration of 1:10 (0.8%) in adenoviral conjunctivitis. Patients with acute conjunctivitis 
or those with corneal involvement, such as ulceration, herpetic keratitis, should be 
referred to an ophthalmologist without further delay. 
General practitioners should not prescribe antibiotics in all cases of viral conjunctivitis, 
rather, they should offer supportive treatments such as cold compress, cleaning the 
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discharges with sterile cotton and sometimes prescribing artificial tears. They may also 
encourage using darker glasses as this not only reduces the photophobia experienced but 
also masks the virulent look of a red and swollen eye. 
2.2.1 Tips on precautions during treatment 
Patient instruction during treatment of viral conjunctivitis: 
 Warning patients on contagious nature. They need to wash hand frequently and to 
avoid direct contact with others 
 They need to be isolated from office/work place and from school at least for couple of 
weeks 
 They need to know that the condition may get worse and should consult doctor 
frequently 
Professional precautions: 
 Hand washing before and after examining such cases 
 Try to avoid contact of instruments 
 If instruments get contaminated try to clean or sterilise. Immersing the instrument with 
1-2% solution of sodium hypochlorite or 3% hydrogen peroxide  is ideal 
2.3 Management of allergic conjunctivitis 
Allergic conjunctivitis comprises a group of diseases affecting the ocular surface and is 
usually associated with type 1 hypersensitivity reactions. Two acute disorders, seasonal 
allergic conjunctivitis and perennial allergic conjunctivitis, exist, as do 3 chronic diseases, 
vernal keratoconjunctivitis, atopic keratoconjunctivitis, and giant papillary conjunctivitis.  
 
 
 
 
 
Fig. 3. Allergic conjunctivitis (Look for follicles and papillae) 
www.intechopen.com
 
Conjunctivitis – A Complex and Multifaceted Disorder 
 
104 
The ocular surface inflammation (usually mast cell driven) results in itching, tearing, lid and 
conjunctival oedema–redness, and photophobia during the acute phase and can lead to a 
classic late-phase response (with associated eosinophilia and neutrophilia) in a subset of 
individuals. As is the case in other allergic diseases, a chronic disease can also develop, 
accompanied by remodelling of the ocular surface tissues. In severe cases, the patient 
experiences extreme discomfort and sustains damage to the ocular surface.  
There are many varieties of both topical and systemic medications available for allergic 
conjunctivitis. It is often too confusing to select any one specifically for a purpose. Table 1 
gives a broad idea on type of medication commonly available for treating allergic 
conjunctivitis with some examples and indications. 
 
 
 
 
 
 
Group Generic name Indications 
Systemic antihistamines 
Cetrizine, Loratidine, 
Fexofenadine etc 
Presence of systemic allergy 
along with conjunctivitis 
Mast cell stabilisers 
Cromolyn sodium, 
Lodoxamide, Nedocromil 
sodium 
Effective in chronic 
conjunctivitis such as vernal 
conjunctivitis 
Antihistamines with added 
property of mast cell 
stabilisation 
Olopatadine, Ketotifen 
Very good response in acute 
allergic conjunctivitis and in 
long run helps in stabilising 
mast cells too 
Topical Steroids 
(Idealy the GPs should refrain 
from prescribing steroids; let 
this group used by 
Ophthalmologists only) 
Fluorometholone, 
Loteprednol 
Used for severe variety of 
allergic conjunctivitis but 
always look for toxicity in 
long term therapy 
Vasoconstrictors Naphazoline/Pheniramine 
Any form of conjunctivitis as 
a support therapy but chronic 
use to be avoided 
Topical NSAIDs Keterolac 
Symptomatic relief of itching 
in severe cases 
 
 
 
Table 1. Summary of commonly available medications for allergic conjunctivitis 
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For such cases, there is no highly effective and safe treatment regimen. Topical 
administration of corticosteroids is used in severe cases but is associated with an 
increased risk for the development of cataracts and glaucoma. Thus, there is a worldwide 
search for new bio targets for the treatment of these diseases. Here, we provide a brief 
update of the clinical symptoms associated with these diseases, the rationale for disease 
classification, recent advances in our understanding of the pathogenesis of the diseases, 
and an update on both preclinical and clinical advances toward refined therapies for these 
diseases. ( Santa JO et al 2005) 
Another variety of conjunctivitis is produced because of the susceptibility of conjunctiva to 
allergens. They may be either exogenic or endogenic in nature. The conjunctival reaction is 
determined by the immune status of individuals. This variety of conjunctivitis is more 
challenging to treat than that resulted out of specific bacterial infections. 
The primary aim of treating a conjunctivitis case is to relieve the common symptoms such 
as ocular itching, grittiness and discharge .Although many of the infective conjunctivitis 
have a self limiting course, patients often go to their General Practitioners or optometrists. 
General practitioners invariably prescribe antibiotics for a faster resolution of the 
symptoms whereas optometrists may offer a range of symptom relieving over the counter 
medication.  
Mast cell stabilisers are another group which are used alone or in combination with steroid 
preparations. Commonly used are cromolyn sodium and lodoxamide (Alomide). Olopatadine 
(Patanol), nedocromil (Alocril), and ketotifen (Zaditor) . Nonsteroidal anti-inflammatory drugs 
(NSAIDs) which act on the cyclooxygenase metabolic pathway and inhibit production of 
prostaglandins and thromboxanes are found to be alternative to cortecostroids and can be a 
better option. It is usually safe to prescribe vasoconstrictors in general practice due to the 
relatively low dose and fewer side effects. Common vasoconstrictors include naphazoline, 
phenylephrine, oxymetazoline, and tetrahydrozoline. 
As mono-therapy, oral antihistamines are an excellent choice when attempting to control 
multiple early-phase, and some late-phase, allergic symptoms in the eyes, nose and 
pharynx. Topical antihistaminic agents not only provide faster and superior relief than 
systemic antihistamines, but they may also possess a longer duration of action than other 
classes including vasoconstrictors, pure mast cell stabilisers, NSAIDs and corticosteroids.  
Unfortunately, despite their efficacy in relief of allergic symptoms, systemic antihistamines 
may result in unwanted adverse effects, such as drowsiness and dry mouth. Newer second-
generation antihistamines (cetirizine, fexofenadine, loratadine and desloratadine) are 
preferred over first-generation antihistamines in order to avoid the sedative and 
anticholinergic effects that are associated with first-generation agents. Finally it can be 
said that when the allergic symptom or complaint, such as ocular pruritus, is isolated, 
focused therapy with topical (ophthalmic) antihistamines is often efficacious and clearly 
superior to systemic antihistamines, either as monotherapy or in conjunction with an oral 
or intranasal agent. 
Topical cyclosporine A is an effective treatment in the management of severe allergic 
conjunctivitis refractory to other medications mentioned earlier. It has additional benefit as a 
steroid-sparing agent. ( Ozcan et al 2007) 
In spite of using all the verities of above mentioned topical preparations allergic 
conjunctivitis sometimes more challenging and frustrating in general practice. They often 
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prompted for using steroid eye drops. The use of corticosteroid should aim at relatively 
weak steroids, such as rimexolone, medrysone, and fluorometholone, that tend to have less 
potency with fewer ocular adverse effects but can be prescribed for a longer durations. 
Topical corticosteroids may be considered for severe seasonal ocular allergy symptoms, 
although long-term use should be avoided because of risks of ocular adverse effects, 
including glaucoma and cataract formation. (Leonard B et al 2005).So it is better advisable 
for GPs not to start steroid eye drops. 
Having said this, although the treatment for allergic conjunctivitis has markedly 
expanded in recent years, providing opportunities for more focused therapy, it often 
leaves both physicians and patients confused over the variety of options. Therefore a 
proper assurance and frequent counselling to the sufferers holds the key to successful 
management of allergic conjunctivitis. 
2.3.1 Atopic keratoconjunctivitis 
AKC is a bilateral inflammation of conjunctiva and eyelids, which has a strong association 
with atopic dermatitis. It is also a type I hypersensitivity disorder with many similarities to 
VKC, yet AKC is distinct in a number of ways. 
In 1953, Hogan first described the association between atopic dermatitis and conjunctival 
inflammation.1 He reported 5 cases of conjunctival inflammation in male patients with 
atopic dermatitis.1 Atopic dermatitis is a common hereditary disorder that usually has its 
onset in childhood; symptoms may regress with advancing age. Approximately 3% of the 
population is afflicted with atopic dermatitis, and, of these, approximately 25% have ocular 
involvement. General practitioners should try with antihistamines and if not responding 
should refer the cases to Ophthalmologists. 
2.3.2 Giant papillary conjunctivitis (GPC) 
GPC is an immune-mediated inflammatory disorder of superior tarsal conjunctiva. As the 
name implies, the primary finding is the presence of “giant” papillae, which are typically 
greater than 0.3 mm in diameter. It is believed that GPC represents an immunologic 
reaction to a variety of foreign bodies, which may cause prolonged mechanical irritation 
to the superior tarsal conjunctiva. Although contact lenses (hard and soft) are the most 
common irritant, ocular prostheses, extruded scleral buckles, and exposed sutures 
following previous surgical intervention may precipitate GPC. Topical mast cell 
stabilisers can be given to such cases. 
2.3.3 Follow-up of allergic conjunctivitis cases 
Follow up is an important strategy while treating allergic conjunctivitis because of the 
following purposes 
 GPs need to diagnose steroid related complication or steroid dependence early so that 
idiosyncrasy is saved 
 GPs should go for change of medication or to go for some combination therapy if the 
initial response found ineffective. 
 GPs should provide health education during all visits so that avoidance of allergy 
sensitive factors become a habit of the individual 
 GPs should provide assurance to the cases and their relatives on every follow up. 
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Type of 
Conjunctivitis 
Clinical features Treatment Prevention 
Bacterial 
Conjunctivitis 
Red eye 
Photophobia 
Discharge 
Cleanliness of eyes 
Symptomatic 
If Antibiotics : 
1. Ciprofloxacin, 
Ofloxacin, 
Gatifloxacin, 
Moxyfloxacin, 
2. Chloramphenicol 
3. Gentamycin 
Hand washing 
Avoid share of 
napkins 
Cleaning and 
disinfectiveness 
of instruments 
used 
Avoid contact 
lens 
Viral 
Conjunctivitis 
Red eye 
Watering of eye 
Mild itching 
Sometimes with subconjunctival 
haemorrhage 
Presence of follicles 
Mostly symptomatic 
with the use of cold 
compress 
In longstanding cases 
might prescribe 
antibiotics for 
secondary infection. 
No substantial benefit 
of antivirals. 
Personal 
hyegine:Washing 
hands  
Disinfect the 
instruments used 
Allergic 
Conjunctivitis 
Red eye 
Intense Itching 
Lacrimation 
Cobblrestone appearance 
Giant paoillae 
Tranta’s spot 
Presence of mucus threads 
Assurance 
1. Steroid eye drops 
2. Antihistamine eye 
drops 
3. Disodium 
chromoglycate eye 
drops 
4. Lodoxamide eye drop
5. Olapatadine eye drop
Avoidance of 
allergy 
Desensitisation 
in some cases 
Conjunctivitis 
from 
Immunological 
Red eye 
Dry eye 
Involvement of cornea and 
sclera 
Presence of systemic features 
depending on the case 
Lubricant eye drops 
Corticosteroids in some 
cases 
Topical NSAIDs 
Periodic 
Ophthalmic 
checkups in the 
presence of 
systemic 
immunological 
disorders 
Other forms of 
conjunctivitis 
1. Cicatrizing 
conjunctivitis 
2. Superior 
limbic 
conjunctivitis 
 
 
1.Dry eye,conjunctival 
scarring,corneal involvement 
2.Foreign body 
sensation,photophobia,mucoid 
discharge & dry eye 
1. Topical 
steroids,topical 
lubricating 
agents,surgical repair 
2. Topical 
lubricants,Mast cell 
stabilisers 
 
Table 2. A quick guide to the diagnosis and treatment of various forms of conjunctivitis by 
general practitioners 
www.intechopen.com
 
Conjunctivitis – A Complex and Multifaceted Disorder 
 
108 
2.4 Management of conjunctivitis from immunological reactions 
Some examples of conjunctivitis resulted out of immunological reactions are cicatricial 
pemphigoid, conjunctivitis in erythema multiform, conjunctival reaction in Stevens Johnson 
syndrome etc..In most form of these immunological conjunctivitis there use to be great 
amount of scarring and cicatrisation of conjunctival tissue. The treatment of these conditions 
may require some surgical approach apart from medicinal therapy. Hence these are out of 
scope in treating at the hand of general practitioners. However, GPs should be aware of 
such conditions and it would not be a bad idea from their side to start topical antibiotic 
earliest to avoid secondary infections. They should know to start topical antibiotics along 
with steroid if happen to see a case of Stevens Johnson syndrome. They should also be able 
to counsel the cases on severity of such cases and inform the cases regarding possible 
surgical interventions like ocular surface reconstruction, keratoprosthesis etc. 
3. Preventive aspects of various forms of conjunctivitis 
Prevention of infective conjunctivitis relies primarily on good personal hygiene. The 
bacterial conjunctivitis is uncommon but can be spread by the hands or from upper 
respiratory tract infections. Gonnoccal infection is transmitted from the genital tract or urine 
to the eye by hands. This is a serious breach of normal hygiene. Ophthalmia neonatorum 
can be prevented by the use of povidone iodine drops, tetracycline eye ointment or other 
antiseptics or antibiotics at birth.  
Viral conjunctivitis can sweep through a community or an institution such as a school very 
rapidly. This is highly infectious and needs to be controlled by the enforcement of strict 
hygiene standards. Contamination through possible articles like towels, face cloths and 
hands need to be avoided. Prevention of allergic conjunctivitis is not possible unless the 
patient is able to change his or her environment or job or identify the allergen causing the 
allergy and remove it, e.g., pollen, animal fur. Drugs such as atropine, neomycin can cause 
allergy and needs prompt withdrawal if detected. 
4. Conclusion 
Conjunctivitis is very frustrating and has social implications especially at work places if it 
is not treated comprehensively. General Practitioners must remain vigilant when 
suspecting conjunctivitis and have the ability to quickly determine whether it has been 
caused by bacteria, viruses or allergens. They should know that a past history of 
infectious conjunctivitis and complaints of itching invariably excludes the possibility of 
bacterial conjunctivitis, whereas complaints such as glued eye are indicative of bacterial 
conjunctivitis. 
Another fact that general practitioners must take into consideration is that viral 
conjunctivitis is more prevalent and has a stronger tendency to recur than a bacterial 
conjunctivitis. Conjunctivitis with a dominant itch indicates an allergic cause.  Failure to 
differentiate what the cause is may lead to wrong treatment and may, in some cases, 
prolong treatment. It must also be noted that General Practitioners should also remain 
aware of the differential diagnoses, such as uveitis, acute congestive glaucoma and 
instruct patients to seek follow-up care if the expected improvement does not occur or if 
vision becomes affected.  
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